398 related articles for article (PubMed ID: 36831264)
1. TDP-43 Proteinopathy Specific Biomarker Development.
Cordts I; Wachinger A; Scialo C; Lingor P; Polymenidou M; Buratti E; Feneberg E
Cells; 2023 Feb; 12(4):. PubMed ID: 36831264
[TBL] [Abstract][Full Text] [Related]
2. TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes.
Tan RH; Kril JJ; Fatima M; McGeachie A; McCann H; Shepherd C; Forrest SL; Affleck A; Kwok JB; Hodges JR; Kiernan MC; Halliday GM
Brain; 2015 Oct; 138(Pt 10):3110-22. PubMed ID: 26231953
[TBL] [Abstract][Full Text] [Related]
3. In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use.
López-Carbonero JI; García-Toledo I; Fernández-Hernández L; Bascuñana P; Gil-Moreno MJ; Matías-Guiu JA; Corrochano S
Transl Neurodegener; 2024 Jun; 13(1):29. PubMed ID: 38831349
[TBL] [Abstract][Full Text] [Related]
4. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.
Riku Y; Iwasaki Y; Ishigaki S; Akagi A; Hasegawa M; Nishioka K; Li Y; Riku M; Ikeuchi T; Fujioka Y; Miyahara H; Sone J; Hattori N; Yoshida M; Katsuno M; Sobue G
Brain; 2022 Aug; 145(8):2769-2784. PubMed ID: 35274674
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of TDP-43 Proteinopathy Onset and Propagation.
Chen HJ; Mitchell JC
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199367
[TBL] [Abstract][Full Text] [Related]
6. Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia.
Pasetto L; Grassano M; Pozzi S; Luotti S; Sammali E; Migazzi A; Basso M; Spagnolli G; Biasini E; Micotti E; Cerovic M; Carli M; Forloni G; De Marco G; Manera U; Moglia C; Mora G; Traynor BJ; Chiò A; Calvo A; Bonetto V
Brain; 2021 Dec; 144(12):3710-3726. PubMed ID: 34972208
[TBL] [Abstract][Full Text] [Related]
7. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD.
Kumar S; Phaneuf D; Cordeau P; Boutej H; Kriz J; Julien JP
Mol Neurodegener; 2021 Jan; 16(1):1. PubMed ID: 33413517
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA NEAT1_1 ameliorates TDP-43 toxicity in in vivo models of TDP-43 proteinopathy.
Matsukawa K; Kukharsky MS; Park SK; Park S; Watanabe N; Iwatsubo T; Hashimoto T; Liebman SW; Shelkovnikova TA
RNA Biol; 2021 Nov; 18(11):1546-1554. PubMed ID: 33427561
[TBL] [Abstract][Full Text] [Related]
9. TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration.
Gao J; Wang L; Yan T; Perry G; Wang X
Mol Cell Neurosci; 2019 Oct; 100():103396. PubMed ID: 31445085
[TBL] [Abstract][Full Text] [Related]
10. TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioral variant frontotemporal dementia.
Halliday GM; Kiernan MC; Kril JJ; Mito R; Masuda-Suzukake M; Hasegawa M; McCann H; Bartley L; Dobson-Stone C; Kwok JBJ; Hornberger M; Hodges JR; Tan RH
J Neurol Sci; 2016 Jul; 366():197-201. PubMed ID: 27288806
[TBL] [Abstract][Full Text] [Related]
11. Glial TDP-43 and TDP-43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes.
Prater KE; Latimer CS; Jayadev S
Glia; 2022 Feb; 70(2):239-255. PubMed ID: 34558120
[TBL] [Abstract][Full Text] [Related]
12. Stathmin-2: adding another piece to the puzzle of TDP-43 proteinopathies and neurodegeneration.
Glass JD
J Clin Invest; 2020 Nov; 130(11):5677-5680. PubMed ID: 33074248
[TBL] [Abstract][Full Text] [Related]
13. Disease animal models of TDP-43 proteinopathy and their pre-clinical applications.
Liu YC; Chiang PM; Tsai KJ
Int J Mol Sci; 2013 Oct; 14(10):20079-111. PubMed ID: 24113586
[TBL] [Abstract][Full Text] [Related]
14. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43.
Mann JR; Gleixner AM; Mauna JC; Gomes E; DeChellis-Marks MR; Needham PG; Copley KE; Hurtle B; Portz B; Pyles NJ; Guo L; Calder CB; Wills ZP; Pandey UB; Kofler JK; Brodsky JL; Thathiah A; Shorter J; Donnelly CJ
Neuron; 2019 Apr; 102(2):321-338.e8. PubMed ID: 30826182
[TBL] [Abstract][Full Text] [Related]
15. The era of cryptic exons: implications for ALS-FTD.
Mehta PR; Brown AL; Ward ME; Fratta P
Mol Neurodegener; 2023 Mar; 18(1):16. PubMed ID: 36922834
[TBL] [Abstract][Full Text] [Related]
16. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies.
Geser F; Lee VM; Trojanowski JQ
Neuropathology; 2010 Apr; 30(2):103-12. PubMed ID: 20102519
[TBL] [Abstract][Full Text] [Related]
17. TDP-43: a novel neurodegenerative proteinopathy.
Forman MS; Trojanowski JQ; Lee VM
Curr Opin Neurobiol; 2007 Oct; 17(5):548-55. PubMed ID: 17936612
[TBL] [Abstract][Full Text] [Related]
18. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.
Hayes LR; Kalab P
Neurotherapeutics; 2022 Jul; 19(4):1061-1084. PubMed ID: 35790708
[TBL] [Abstract][Full Text] [Related]
19. Endogenous retroviruses and TDP-43 proteinopathy form a sustaining feedback driving intercellular spread of Drosophila neurodegeneration.
Chang YH; Dubnau J
Nat Commun; 2023 Feb; 14(1):966. PubMed ID: 36810738
[TBL] [Abstract][Full Text] [Related]
20. A feedback loop between dipeptide-repeat protein, TDP-43 and karyopherin-α mediates C9orf72-related neurodegeneration.
Solomon DA; Stepto A; Au WH; Adachi Y; Diaper DC; Hall R; Rekhi A; Boudi A; Tziortzouda P; Lee YB; Smith B; Bridi JC; Spinelli G; Dearlove J; Humphrey DM; Gallo JM; Troakes C; Fanto M; Soller M; Rogelj B; Parsons RB; Shaw CE; Hortobágyi T; Hirth F
Brain; 2018 Oct; 141(10):2908-2924. PubMed ID: 30239641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
